Inventor · disambiguated record
Diana Graus Porta
Also filed as: GRAUS PORTA DIANA
8 granted patents·16 pending applications·74 citations·filing 2007–2022
81Inventor score
Top patents by PatentIndex Score
24 records- 0197US8815901B2Quinoline carboxamide derivatives as protein tyrosine kinase inhibitorsNOVARTIS AG·Filed 2013·Granted Aug 26, 2014·69 cites·9 claims
- 0278US10130629B2Pharmaceutical combinationsNOVARTIS AG·Filed 2016·Granted Nov 20, 2018·3 cites·7 claims
- 0375US10028955B2FGFR inhibitor for use in the treatment of hypophosphatemic disordersNOVARTIS AG·Filed 2016·Granted Jul 24, 2018·2 cites·6 claims
- 0467US8273882B2Quinoxaline carboxamide derivatives as protein tyrosine kinase inhibitorsFURET PASCAL·Filed 2009·Granted Sep 25, 2012·0 cites·22 claims
- 0563US2021308132A1Fgfr inhibitor for use in the treatment of hypophosphatemic disordersNOVARTIS AG·Filed 2018·Application pending·0 cites
- 0661US2014378468A1N-Oxide of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1--1-methyl-ureaAICHHOLZ REINER·Filed 2014·Application pending·0 cites
- 0758US8674099B2Quinoxaline carboxamide derivatives as protein tyrosine kinase inhibitorsFURET PASCAL·Filed 2012·Granted Mar 18, 2014·0 cites·7 claims
- 0857US8536175B2Quinoxaline carboxamide derivatives as protein tyrosine kinase inhibitorsFURET PASCAL·Filed 2012·Granted Sep 17, 2013·0 cites·12 claims
- 0956US10507201B2Use of ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitorsNOVARTIS AG·Filed 2019·Granted Dec 17, 2019·0 cites·17 claims
- 1056US2024366567A1Pharmaceutical combinations comprising a kras g12c inhibitor and uses thereof for the treatment of cancersNOVARTIS AG·Filed 2022·Application pending·0 cites
- 1156US2011045511A1Methods of monitoring the modulation of the kinase activity of fibroblast growth factor receptor and uses of said methodGRAUS PORTA DIANA·Filed 2009·Application pending·0 cites
- 1254US2010075337A1Method of identification of cells that show sensitivity to modulation of signalingh mediated by fibroblast growth factor receptor or a variant thereofGRAUS PORTA DIANA·Filed 2008·Application pending·0 cites
- 1353US2024082218A1Pharmaceutical combinations comprising a kras g12c inhibitor and uses of a kras g12c inhibitor for the treatment of cancersNOVARTIS AG·Filed 2021·Application pending·0 cites
- 1453US2012315648A1Method of identification of cells that show sensitivity to modulation of signaling mediated by a fibroblast growth factor receptor or a variant thereofGRAUS PORTA DIANA·Filed 2012·Application pending·0 cites
- 1552US2023090389A1A triple pharmaceutical combination comprising dabrafenib, an erk inhibitor and a shp2 inhibitorNOVARTIS AG·Filed 2021·Application pending·0 cites
- 1652US2015323548A1Methods of monitoring the modulation of the kinase activity of fibroblast growth factor receptor and uses of said methodsGRAUS PORTA DIANA·Filed 2015·Application pending·0 cites
- 1751US2015072019A1Fgfr inhibitor for use in the treatment of hypophosphatemic disordersNOVARTIS AG·Filed 2013·Application pending·0 cites
- 1850US2016102062A1N-Oxide of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1--1-methyl-ureaAICHHOLZ REINER·Filed 2015·Application pending·0 cites
- 1950US2009062320A1Method of Treating Disorders Mediated by the Fibroblast Growth Factor ReceptorGUAGNANO VITO·Filed 2007·Application pending·0 cites
- 2048US2012220600A1N-Oxide of 3-(2,6-dichloro-3,5-dimethoxy-phenyl) -1--1-methyl-ureaAICHHOLZ REINER·Filed 2010·Application pending·0 cites
- 2146US2018185341A1Use of ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitorsNOVARTIS AG·Filed 2015·Application pending·0 cites
- 2239US2016095842A1Combination therapy containing a pi3k-alpha inhibitor and fgfr kinase inhibitor for treating cancerFRITSCH CHRISTINE·Filed 2014·Application pending·0 cites
- 2338US2010120773A1Method of treating disorders mediated by the fibroblast growth factor receptorGUAGNANO VITO·Filed 2010·Application pending·0 cites
- 2432US11229643B2Combinations of FGFR4 inhibitors and bile acid sequestrantsNOVARTIS AG·Filed 2017·Granted Jan 25, 2022·0 cites·12 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →